JP5808392B2 - ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法 - Google Patents

ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法 Download PDF

Info

Publication number
JP5808392B2
JP5808392B2 JP2013506566A JP2013506566A JP5808392B2 JP 5808392 B2 JP5808392 B2 JP 5808392B2 JP 2013506566 A JP2013506566 A JP 2013506566A JP 2013506566 A JP2013506566 A JP 2013506566A JP 5808392 B2 JP5808392 B2 JP 5808392B2
Authority
JP
Japan
Prior art keywords
salt
water
mixture
methanesulfonate
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013506566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528577A (ja
JP2013528577A5 (OSRAM
Inventor
ジヨルダーノ，クラウデイオ
バルトフオーゲル，エルビン
Original Assignee
ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー filed Critical ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー
Publication of JP2013528577A publication Critical patent/JP2013528577A/ja
Publication of JP2013528577A5 publication Critical patent/JP2013528577A5/ja
Application granted granted Critical
Publication of JP5808392B2 publication Critical patent/JP5808392B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013506566A 2010-04-27 2011-04-06 ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法 Active JP5808392B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10161207.5 2010-04-27
EP10161207 2010-04-27
PCT/EP2011/055309 WO2011134763A1 (en) 2010-04-27 2011-04-06 Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015104930A Division JP6345154B2 (ja) 2010-04-27 2015-05-22 ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法

Publications (3)

Publication Number Publication Date
JP2013528577A JP2013528577A (ja) 2013-07-11
JP2013528577A5 JP2013528577A5 (OSRAM) 2015-03-05
JP5808392B2 true JP5808392B2 (ja) 2015-11-10

Family

ID=42634917

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013506566A Active JP5808392B2 (ja) 2010-04-27 2011-04-06 ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法
JP2015104930A Active JP6345154B2 (ja) 2010-04-27 2015-05-22 ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法
JP2017106571A Active JP6450420B2 (ja) 2010-04-27 2017-05-30 ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015104930A Active JP6345154B2 (ja) 2010-04-27 2015-05-22 ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法
JP2017106571A Active JP6450420B2 (ja) 2010-04-27 2017-05-30 ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法

Country Status (27)

Country Link
US (2) US9505708B2 (OSRAM)
EP (1) EP2563355B1 (OSRAM)
JP (3) JP5808392B2 (OSRAM)
KR (1) KR101851118B1 (OSRAM)
CN (2) CN102858330B (OSRAM)
AR (1) AR085171A1 (OSRAM)
AU (1) AU2011246707B2 (OSRAM)
BR (1) BR112012027623B1 (OSRAM)
CA (1) CA2794389C (OSRAM)
CY (1) CY1117879T1 (OSRAM)
DK (1) DK2563355T3 (OSRAM)
EA (1) EA021389B1 (OSRAM)
ES (1) ES2590128T3 (OSRAM)
HR (1) HRP20161077T1 (OSRAM)
HU (1) HUE030504T2 (OSRAM)
IL (1) IL222532A (OSRAM)
LT (1) LT2563355T (OSRAM)
ME (1) ME02509B (OSRAM)
MX (1) MX342697B (OSRAM)
NZ (2) NZ700221A (OSRAM)
PL (1) PL2563355T3 (OSRAM)
PT (1) PT2563355T (OSRAM)
RS (1) RS55084B1 (OSRAM)
SI (1) SI2563355T1 (OSRAM)
SM (1) SMT201600266B (OSRAM)
TW (1) TWI492919B (OSRAM)
WO (1) WO2011134763A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015180664A (ja) * 2010-04-27 2015-10-15 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103804341B (zh) * 2012-11-13 2018-04-10 中国人民解放军军事医学科学院毒物药物研究所 酰胺衍生物及其医药用途
CN104761531B (zh) * 2014-01-03 2017-12-01 中国人民解放军军事医学科学院毒物药物研究所 镇痛活性化合物及其医药用途
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20040213842A1 (en) * 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
BRPI0413982A (pt) 2003-08-25 2006-11-07 Newron Pharm Spa derivados de alfa-aminoamida úteis como agentes anti-inflamatórios
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
KR101277520B1 (ko) * 2004-09-10 2013-06-21 뉴론 파마슈티칼즈 에스. 피. 에이. （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
JP5240476B2 (ja) 2006-06-19 2013-07-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法
JP5315674B2 (ja) * 2007-11-19 2013-10-16 セントラル硝子株式会社 非水電池用電解液及びこれを用いた非水電池
DK2229351T3 (en) * 2007-12-11 2018-01-22 Newron Pharm Spa PROCEDURE FOR THE PREPARATION OF 2- [4- (3- OR 2-FLUORBENZYLOXY) BENZYLAMINO] PROPANAMIDS WITH HIGH PURITY
JP5736175B2 (ja) 2007-12-19 2015-06-17 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー 精神障害の治療に有用なα−アミノアミド誘導体
WO2009109334A1 (en) 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
SI2563355T1 (sl) * 2010-04-27 2016-10-28 Newron Pharmaceuticals S.P.A. Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015180664A (ja) * 2010-04-27 2015-10-15 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法

Also Published As

Publication number Publication date
HK1179881A1 (en) 2013-10-11
CN102858330B (zh) 2015-07-22
BR112012027623B1 (pt) 2021-07-06
SI2563355T1 (sl) 2016-10-28
AU2011246707B2 (en) 2014-11-20
EA021389B1 (ru) 2015-06-30
JP2013528577A (ja) 2013-07-11
US20170029365A1 (en) 2017-02-02
EP2563355A1 (en) 2013-03-06
CA2794389A1 (en) 2011-11-03
JP2015180664A (ja) 2015-10-15
ES2590128T3 (es) 2016-11-18
LT2563355T (lt) 2016-09-26
CA2794389C (en) 2016-08-23
HK1213872A1 (zh) 2016-07-15
IL222532A0 (en) 2012-12-31
MX342697B (es) 2016-10-10
EA201291116A1 (ru) 2013-04-30
NZ602648A (en) 2014-10-31
US20130039983A1 (en) 2013-02-14
SMT201600266B (it) 2016-08-31
CY1117879T1 (el) 2017-05-17
EP2563355B1 (en) 2016-06-08
KR20130094212A (ko) 2013-08-23
DK2563355T3 (en) 2016-09-12
TWI492919B (zh) 2015-07-21
HRP20161077T1 (hr) 2016-10-21
US9856207B2 (en) 2018-01-02
HUE030504T2 (en) 2017-05-29
TW201139344A (en) 2011-11-16
IL222532A (en) 2017-09-28
CN105037188A (zh) 2015-11-11
MX2012012093A (es) 2012-12-17
JP6345154B2 (ja) 2018-06-20
JP2017197553A (ja) 2017-11-02
WO2011134763A1 (en) 2011-11-03
PL2563355T3 (pl) 2016-12-30
US9505708B2 (en) 2016-11-29
BR112012027623A2 (pt) 2016-08-09
CN102858330A (zh) 2013-01-02
NZ700221A (en) 2016-04-29
CN105037188B (zh) 2017-06-23
AR085171A1 (es) 2013-09-18
ME02509B (me) 2017-02-20
RS55084B1 (sr) 2016-12-30
KR101851118B1 (ko) 2018-04-23
PT2563355T (pt) 2016-09-02
JP6450420B2 (ja) 2019-01-09

Similar Documents

Publication Publication Date Title
JP6450420B2 (ja) ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法
JP6028016B2 (ja) リナグリプチンベンゾエートの多形体
JP6211072B2 (ja) ダサチニブと、選択された共結晶形成剤とを含んでなる多成分結晶
AU2011246707A1 (en) Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers
WO2011095985A2 (en) Rasagiline salts and processes for the preparation thereof
WO2024097394A1 (en) Solid and co-crystal forms of a pyrimidine triazole compound
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
US9266822B2 (en) Solid forms of tacedinaline
HK1179881B (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
HK1213872B (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
EP1942100A1 (en) Amorphous and crystalline forms of rivastigmine hydrogentartrate
WO2021259732A1 (en) Multi-component compounds comprising zanubrutinib and a benzoic acid derivative
WO2012003413A1 (en) Novel solid forms of tacedinaline
EP3181565A1 (en) Crystalline omarigliptin salts
CN109053717A (zh) 一种罗格列酮龙胆酸盐及其制备方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150811

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150908

R150 Certificate of patent or registration of utility model

Ref document number: 5808392

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250